1. Scrip
  2. >>Business
  3. >>Stock Watch

Stock Watch: All Bayer’s Roads Lead To Unpalatable

After A Spate Of Disasters, Few Good Options Remain

 
• By Andy Smith

Investors reacted quite differently to Bayer’s first-quarter results and those of its licensing partner Regeneron. There are sound reasons for this. It seems unlikely that one will help the other.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

When the European conglomerate Bayer AGreported its first-quarter 2024 results, it summarized its performance with “as expected.” Investors on the other hand, who are probably still seething from their dividends being slashed to the legally allowed token, were not as relaxed and Bayer’s stock price closed down by about 1% compared to the NYSE Arca Pharmaceutical Index’s same day close modestly into positive territory. With group sales that fell by 4% on the first quarter of 2023 but rose by 16% on the fourth quarter of 2023 to miss analysts’ consensus estimates by 2%, Bayer brought first-quarter healthcare earnings season to a close with a whimper. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Stock Watch

More from Business

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.